India, May 29 -- Teva Pharmaceutical Industries Ltd. (TEVA) reaffirmed 2027 financial targets, including 30% operating profit margin, driven by growth and transformation programs. The company said its medicines franchise is on track to exceed $5 billion by 2030. AUSTEDO sales are expected to exceed $2.5 billion in sales by 2027 and exceed $3 billion by 2030.
Richard Francis, Teva's President and CEO, said: "Now, we are accelerating our growth into a leading biopharma company with a strong innovative medicines franchise and a powerhouse generics and biosimilars portfolio."
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services with permission from RT...